Company | Cap $ | P/E | P/B | P/S | ROE | ROA | ROS | L/A | P/FCF | PR | Period |
---|---|---|---|---|---|---|---|---|---|---|---|
C4 Therapeutics | 327 | 2023q2 | |||||||||
Canopy Growth | 702 | 2024q3 | |||||||||
CanSino Biologics | 530 | 2024q1 | |||||||||
Capricor Therapeutics | 154 | 2023q3 | |||||||||
CARA Therapeutics | 47 | 2021 | |||||||||
Cardinal Health | 25,564 | 2024q2 | |||||||||
CareDx | 516 | 2023q3 | |||||||||
Carl Zeiss Meditec | 5,776 | 2022 | |||||||||
Cassava Sciences | 1,231 | 2021 | |||||||||
Catalent | 10,068 | 2024 | |||||||||
Centene | 34,309 | 2023q2 | |||||||||
Certara | 2,546 | 2023q3 | |||||||||
Champions Oncology | 66 | 2024q2 | |||||||||
Charles River Laboratorie... | 11,645 | 2023 | |||||||||
Check-Cap | 182 | 2021 | |||||||||
Chemed | 9,085 | 2022 | |||||||||
Cipla | 13,230 | 2022 | |||||||||
Citius Pharmaceuticals | 65 | 2023q3 | |||||||||
Clover Health Investments | 400 | 2023q3 | |||||||||
Co-Diagnostics | 36 | 2023q3 |